FBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinoma.

Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer (2006) 6.76

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32

Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78

SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69

Gastric cancer: epidemiology, pathology and treatment. Ann Oncol (2003) 2.53

Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med (2007) 1.99

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68

p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res (2009) 1.37

Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol (2012) 1.17

Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res (2012) 1.15

The two faces of FBW7 in cancer drug resistance. Bioessays (2011) 1.08

MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. J Exp Clin Cancer Res (2015) 1.02

The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int J Cancer (2014) 1.00

Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer (2002) 0.95

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One (2014) 0.94

FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs. Mol Cancer Res (2013) 0.94

Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells. Hepatology (2011) 0.90

MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulation. Oncogenesis (2016) 0.88

mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. Mol Cell Biol (2015) 0.84

Chemotherapy in gastric cancer: a never ending saga. Ann Oncol (2003) 0.82

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer (2013) 0.82

Fbxw7-associated drug resistance is reversed by induction of terminal differentiation in murine intestinal organoid culture. Mol Ther Methods Clin Dev (2016) 0.81

Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Cancer Chemother Pharmacol (2014) 0.77